PhaseBio Pharmaceuticals Inc
PHASDelisted Dec 21, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001169245
PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:35 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $131.1M (1210.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2022 | – | Mar 30, 2020 | Mar 26, 2019 |
| Revenue | $10.8M | $320.0K | $2.36M | $668.0K |
| Operating expenses | $118.2M | $85.2M | $42.1M | $20.3M |
| Research and development | $102.1M | $72.1M | $30.9M | $15.5M |
| Selling, general and administrative | $16.1M | $13.1M | $11.2M | $4.86M |
| Operating income | -$107.4M | -$84.9M | -$39.7M | -$19.6M |
| Interest expense | $947.0K | $1.45M | $1.08M | $3.92M |
| Income tax | $1.60M | $0 | $0 | $0 |
| Net income | -$131.1M | -$98.6M | -$39.2M | -$23.8M |
| EPS, basic | $-2.98 | – | – | – |
| EPS, diluted | $-2.98 | – | – | – |
| Weighted shares, basic | 43.9M | – | – | – |
| Weighted shares, diluted | 43.9M | – | – | – |
| Margins and growth | ||||
| Operating margin | -991.2% | -26517.5% | -1683.0% | -2940.7% |
| Net margin | -1210.1% | -30801.6% | -1662.3% | -3569.8% |
| Revenue growth, year over year | +3,284.7% | −86.4% | +253.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2022 | – | Mar 30, 2020 | Mar 26, 2019 |
| Cash and equivalents | $41.8M | $28.1M | $74.0M | $61.0M |
| Total current assets | $48.8M | $40.1M | $78.8M | $62.6M |
| Property, plant and equipment | $10.2M | $8.22M | $1.92M | $355.0K |
| Total assets | $60.5M | $50.4M | $82.5M | $63.0M |
| Accounts payable | $12.6M | $3.67M | $2.92M | $1.81M |
| Short-term debt | $5.41M | $5.36M | $2.38M | – |
| Total current liabilities | $27.9M | $15.0M | $8.48M | $4.58M |
| Long-term debt | $1.36M | $6.77M | $12.3M | $7.50M |
| Total liabilities | $153.6M | $75.6M | $22.5M | $12.1M |
| Shareholders' equity | -$93.0M | -$25.2M | $60.0M | $50.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2022 | – | Mar 30, 2020 | Mar 26, 2019 |
| Operating cash flow | -$47.4M | -$60.0M | -$39.6M | -$17.1M |
| Capital expenditures | $2.68M | $1.31M | $960.0K | $119.0K |
| Free cash flow | -$50.1M | -$61.3M | -$40.6M | -$17.2M |
| Depreciation and amortization | $1.79M | $508.0K | $174.0K | $105.0K |
| Stock-based compensation | $2.27M | $2.24M | $1.42M | $332.0K |
| Investing cash flow | -$2.68M | -$1.41M | -$960.0K | -$119.0K |
| Financing cash flow | $63.8M | $15.5M | $53.5M | $64.8M |
| Net change in cash | $13.7M | -$45.9M | $13.0M | $47.6M |
| Ratio | ||||
| Stock-based compensation, % of revenue | 20.9% | 699.1% | 60.2% | 49.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 8, 2022 | 49.9M | +3.8% | SEC |
| May 10, 2022 | 48.7M | +1.5% | SEC |
| Mar 21, 2022 | 48.7M | +65.4% | SEC |
| Nov 8, 2021 | 48.1M | +63.8% | SEC |
| Aug 9, 2021 | 48.0M | +63.7% | SEC |
| May 10, 2021 | 48.0M | +66.6% | SEC |
| Mar 11, 2021 | 29.4M | +2.3% | SEC |
| Nov 6, 2020 | 29.4M | +2.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.